Advertisement

Virostatika in der Dermatologie

  • S. W. Wassilew
  • Th. Nasemann

Zusammenfassung

Virostatica wie Idoxuridin, Vidarabin, Amantadin, Tromantadin, Äthyldesoxyuridin, Inosiplex, Acyclovir, Phosphonoformiat, Bromovinyldesoxyuridin und Fluordesoxyarabinofuranosyljodcytosin werden in bezug auf Angriffspunkte, Wirkmechanismen, bewiesene Wirkungen und Nebenwirkungen diskutiert. Die klinische Wirksamkeit und mögliche Indikationen werden besprochen. Auf Bedeutung und Zukunftsaspekte wird hingewiesen.

Summary

Antiviral drugs, e.g. Idoxuridine, Vidarabine, Amantadine, Tromantadine, Ethyldesoxyuridine, Inosiplex, Acyclovir, Phosphonoformiate, Bromovinyldesoxyuridine and Fluordeoxyarabinofuranosyljodcyto- sin are discussed in respect to working points, mechanisms of action, prooven effects and side effects. Clinical efficacy and possible indications are referred. Significance and futur aspects are pointed out.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abeles, J H.: Inosiplex in recurrent herpes simplex infections. Lancet 23, 926, (1982).CrossRefGoogle Scholar
  2. 2.
    Ahumada, P M.: Zur Wirksamkeit von Tromantadin bei Herpes simplex. Doppelblindstudie. Ther. Gegenw. 116, 100–108 (1977).Google Scholar
  3. 3.
    AI Nakib, W, AI Kandari, S, El Khalik, D M A, El Shirbiny, A M.: A randomised controlled study of intravenous Acyclovir (Zovirax) against placebo in adults with chickenpox. J. Infect. 6, Suppl 1, 49–56 (1983).Google Scholar
  4. 4.
    Balfour, H H jr, Bean, B, Laskin, O L, Ambinder, R F, Meyers, J D, Wade J C.: Acyclovir halts progression of herpes zoster in immunocompromised patients. New Engl. J. Med. 308, 1448–1453 (1983).CrossRefPubMedGoogle Scholar
  5. 5.
    Becker, A.: TK-gene and HSV-resistance. Int. Symp. antiviral compounds and wound healing Hamburg 14. 16. June (1983).Google Scholar
  6. 6.
    Borelli, S, Gehrken, H.: Therapeutische Erfahrungen bei Herpes simplex-Erkrankungen mit Tromantadin-HCl im Doppelblindversuch. Schweiz. Rdsch. Med. (Praxis) 65, 108–110 (1976).Google Scholar
  7. 7.
    Brigden, S, Whiteman, P.: The mechanism of action, pharmacokinetics and toxicity of Acyclovir - a review. J. Infect. 6, Suppl 1, 3–9 (1983).Google Scholar
  8. 8.
    Bryson, Y J, Dillon, M, Lovett, M, Acuna, G, Taylor, S, Cherry, J D.: Treatment of first episodes of genital herpes simplex virus infection with oral Acyclovir. A randomized double-blind controlled trial in normal subjects. New Eng. J. Med. 308, 916–921 (1983).CrossRefPubMedGoogle Scholar
  9. 9.
    Bunta, S, Peris, Z.; Immunstimulierende Zostertherapie (Dreijährige Erfahrungen mit Inosiplex). Z. Hautkr. 56 (22), 1457–1466 (1982).Google Scholar
  10. 10.
    Cheng, Y, Nakayama, K, Derse, D, Bastow, K, Ruth, J, Tan, R, Dutschmann, G, Caradonna, S J, Grill, S.: Herpes virus specific enzymes: properties, physiological roles, and pharmacological implications. In: Herpesvirus. Clinical, pharmacological and basic aspects. Proc. Int. Congr. Ser. Exeerpta Medica 47–56 (1982).Google Scholar
  11. 11.
    Chilf G N, Runne, U.: Intravenöse Zoster-Behandlung mit Acyclovir bei Patienten mit malignen Systemkrankheiten. Hautarzt 34, Suppl. VI, 336–337 (1983).Google Scholar
  12. 12.
    de Clercq, E, Zhang, Z X, Sim, I S.: Treat-ment of experimental herpes virus encephalitis with (E)-5-(2-bromovinyl)-2’-deoxyuridine in mice. Antimicrob. Agents Chemother. 22, 421–425 (1982).PubMedGoogle Scholar
  13. 13.
    Corey, L, Benedetti, J, Critchlow, C, Mertz, G, Douglas, J, Fife, K, Fahnlander, A, Remington, M L, Winter, C, Dragavon, J.: Treatment of primary firstepisode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J. antimicrob. Chemother. 12, Suppl B, 79–88.(1983).PubMedGoogle Scholar
  14. 14.
    Corey, L, Fife, K H, Benedetti, J K, Winter, CA, Fahnlander, A, Connor, J D.: Intravenous acyclovir for the treatment of primary genital herpes. Ann. intern. Med. 98, 914–921 (1982).Google Scholar
  15. 15.
    Corey, L, Holmes, K K, Benedetti, J, Critchlow, C.; Clinical course of genital herpes. In: Nahmias, A J, Dowdle, W R, Schinazi, R F. eds. The human herpes viruses: an interdisciplinary perspective. Elsevier New York pp 496–502.(1981).Google Scholar
  16. 16.
    Crane, L R, Sunstrum, J C, Lerner, A M.: Combination therapy of experimental infection with herpes simplex virus, type 2. Clin. Res. 31, 541 A (1983).Google Scholar
  17. 17.
    Crumpacker, C S, Schnipper, L E, Kowalsky, P N, Sherman, D M.: Resistance of herpes simplex virus to adenine arabinoside and E-5-(2-bromovinyl)2’-deoxyuridine: A physical analysis. J. infect. Dis. 146, 167–172 (1982).CrossRefPubMedGoogle Scholar
  18. 18.
    Crumpacker, C S, Schnipper, L E, Marlowe, S T, Kowalsky, P N, Hershey, B J, Levin, M J.: Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir (1982).Google Scholar
  19. 19.
    Daksis, JI, Priemer, M M, Chan, V L.: Isolation and preliminary characterization of a phosphonoacetic acid-resistant and temperature-sensitive mutant of herpes simplex virus type 1. J. Virol. 42, 20–29 (1982).PubMedGoogle Scholar
  20. 20.
    Dawber, R P R.: Idoxuridine in herpes zoster. Further evaluation of intermittent topical therapy. Brit. med. J. 2, 526–529 (1974).CrossRefPubMedGoogle Scholar
  21. 21.
    Field, H J.: Drug resistance in herpes simplex virus. In: Herpesvirus. Clinical, pharmacological and basic aspects. Proc. Int. Congr. Ser. Experta Medica 205–210.(1982).Google Scholar
  22. 22.
    Fiddian, A P, Yeo, J M, Stubbings, R, Dean, D.: Successful treatment of herpes labialis with topical acyclovir. Brit. med. J. 286, 1699–1701 (1983).CrossRefGoogle Scholar
  23. 23.
    Galbraith, A W: Prevention of postherpetic neuralgia by amantadine hydrochloride (Symmetrel). Brit. J. clin. Pract. 37, 304–306 (1983).PubMedGoogle Scholar
  24. 24.
    Galli, M, Lazzarin, A, Moroni, M, Zanussi, C: Inosiplex in recurrent herpes simplex infections. Lancet II, 331–332.(1982).CrossRefGoogle Scholar
  25. 25.
    Gauri, K K, Wassilew, S W: Chemotherapie bei Virus-Erkrankungen. Offizin. Pharm. 26–42 (1983).Google Scholar
  26. 26.
    Gluckmann, E, Devergie, A, Melo, R, Nebout, T, Lotsberg, J, Zhao, X M.: Prophylaxis of herpes infections after bone -marrow transplantation by oral acyclovir. Lancett II, 706–708 (1983).Google Scholar
  27. 27.
    Gould, J M, Chessells, J M, Marshall, W C, Mendrick, G D W: Acyclovir in herpesvirus infections in children: Experience in an open study with particular reference to safety. J. Infect. 5, 283 -289.(1982).CrossRefGoogle Scholar
  28. 28.
    Hann, IM, Prentice, H G, Blacklock, H A, Ross, M G R, Brigden, D, Rosling, A E.: Acyclovir prophylaxis against herpes virus infections in severely immuncompromised patients: Randomised double blind trial. Brit. med. J. 287, 384–388 (1983).Google Scholar
  29. 29.
    Heidemann, E, Wilms, K, Treuner, J, Niethammer, D.: Fibroblasten-Interferon zur Behandlung des Herpes zoster. Eine Pilotstudie. Dtsch. med. Wschr. 107, 695–697 (1982).CrossRefGoogle Scholar
  30. 30.
    Hellgren, L, Herrmann, L S.: Tromantadine hydrochloride in the treatment of herpes simplex. Dermato-lógica (Basel) 167, 267–272 (1983).CrossRefGoogle Scholar
  31. 31.
    Hofschneider, P H, Obert, HJ.: Vorläufige klinische Erfahrungen mit humanem Fibroblasteninterferon in der Bundesrepublik Deutschland. Verh. Dtsch. Ges. inn. Med. 507- 512.(1982).Google Scholar
  32. 32.
    Janz, C, Wigand, R.: Combined interaction of antiherpes substances and Interferon beta on the multiplication of herpes simplex virus. Arch. Virol. 73, 135–143 (1982).CrossRefPubMedGoogle Scholar
  33. 33.
    Juel-Jensen, B E, Khan, J A, Pasvol, G.: Highdose intravenous acyclovir in the treatment of zoster: A doubleblind placebo-controlled trial. J. Infect. 6, Suppl 1, 31–36 (1983).Google Scholar
  34. 34.
    Kaufman, E.: New understanding of ocular herpetic disease. Amer. J. Ophthal. 94, 119–121 (1982).PubMedGoogle Scholar
  35. 35.
    Krasny, H C, Liao, S H T, Good, S S.: Oral pharmacokinetics and metabolism of the prodrug of acyclovir. A134U, in humans. Clin. Pharmacol. Ther. 33, 256 (1983).Google Scholar
  36. 36.
    Kumor, K M, Woo, J, Conklin, R.: Renal function in immunocompromised patients receiving acyclovir for herpes virus infections. Clin. Res. 30, 253 A (1982).Google Scholar
  37. 37.
    Larkin, M, Ogilvie, M, Mill, J I.: Effect of low dose acyclovir (5 mg/kg) on virus shedding, interferon and humoral immunity in herpes zoster. J. antimicrob. Chemother. 12, 79–87 (1983).CrossRefPubMedGoogle Scholar
  38. 38.
    Leyland, J B, Donnelly, H, Myskowski, P, Donner, A, Groshen, S, Lopez, C.: FIAC, a potent new antiviral agent: Therapeutic superiority over adenine arabinoside (ARA-A) against varicella zoster infections in immunosuppressend patients. Clin. Res. 31, 369A (1983).Google Scholar
  39. 39.
    Leyland, J B, Feinberg, A, Vidal, P, Fanucchi, M, Williams, L, Young, C.: Human metabolism of 24-fluoro-5-jodo-l beta-D-arabinosylcytosine (FIAC). Proc. Amer. Ass. Cancer Res. 24, 136 (1983).Google Scholar
  40. 40.
    Madgal, P C, Uyttebroeck, W, de Clercq, E, Missotten, L.: Oral and topical treatment of experimental herpes simplex iritis with bromovinyldeoxyuridine. Arch. Ophthal. (Chicago) 100, 1337–1340 (1982).Google Scholar
  41. 41.
    Mill, J, Maonald, D R, Fall, C, Donald, G, Mendrick, W, Copplestone, A.: Intravenous acyclovir in acute herpes zoster infection. J. Infect. 6, 157–151 (1983).CrossRefGoogle Scholar
  42. 42.
    Mindel, A, Sutherland, S.: Genital herpes - the disease and this treatment in-cluding intravenous acyclovir. J. antimicrob. Chemother. 12, Suppl. B, 51- 59.(1983).PubMedGoogle Scholar
  43. 43.
    Nasemann, Th.: Viruskrankheiten der Haut, der Schleimhäute und des Genitale. Thieme Stuttgart (1974).Google Scholar
  44. 44.
    Oberg, B.: Antiviral effects of phosphonoformiate (PFA, Foscarnet Sodium). Pharmacol. Ther. 10, 387–415 (1983).Google Scholar
  45. 45.
    Orenstein, WA.: Prophylaxis of varicella in high-risk children: Doseresponse effect of zoster immune globulin. J. Pediat. (St. Louis) 98, 368–373 (1981).Google Scholar
  46. 46.
    Peterslund, NA, Black, F T, Tauris, P.: Impaired renal function after injections of acyclovir. Lancet I, 243–244 (1983).Google Scholar
  47. 47.
    Preiksaitis, J K, Rosno, S, Grumet, C, Merigan, T C.: Infections due to herpesviruses in cardiac transplant recipients: Role of the donor heart and immunosuppressive therapy. J. infect. Dis. 147, 974–981. (1983).CrossRefPubMedGoogle Scholar
  48. 48.
    Prentice, H G, Hann, I M.: Prophylactic studies against herpes infections in severely immunocompromised patients with acyclovir. J. Infect. 6, Suppl. 1, 17–21 (1983).Google Scholar
  49. 49.
    Prober, C G, Kirk, L E, Keeney, R E.: Acyclovir therapy of chickenpox in immunsuppressed children: A collaborative study. J. Pediat. (St. Louis) 101, 622- 625.(1982).Google Scholar
  50. 50.
    Raab, B, Lorincz, A L.: Topical acyclovir caution. J. Amer. Acad. Derm. 124 (1983).Google Scholar
  51. 51.
    Reichman, R C, Badger, G J, Guinan, M E, Nahmias, A J, Keeney, R E, Davis, L G.: Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: A controlled trial. J. infect. Dis. 147, 336–340 (1983).CrossRefPubMedGoogle Scholar
  52. 52.
    Reichman, R C, Badger, G J, Mertz, G J, Corey, L, Richman, D, Oxman, M.: Patient-initiated therapy of recurrent herpes simplex genitalis with orally administered acyclovir. Clin. Res. 31, 373A (1983).Google Scholar
  53. 53.
    Rosenthal, K S, Sokol, M S, Ingram, R L, Subramanian, R, Fort, R C: Tromantadine: Inhibitor of early and late events in herpes simplex virus replication. Antimicrob. Agents Chemother. 22, 1031–1136 (1982).PubMedGoogle Scholar
  54. 54.
    Schneider, W, Schneider, B.: Wirkungen und Nebenwirkungen der topischen Therapie bei Herpes simplex-Infektionen der Haut. Therapiewoche 32, 5352–5358 (1982).Google Scholar
  55. 55.
    Schoeßnius, H H.: Moderne Therapie des Herpes simplex. Med. Klin. 78, 91–94 (1983).Google Scholar
  56. 56.
    Shigeta, S, Yokota, T, Iwabuchi, T, Baba, M, Konno, K, Ogata, M.: Comparative efficacy of antiherpes drugs against various strains of varicella zoster virus. J. infect. Dis. 147, 576–584 (1983).CrossRefPubMedGoogle Scholar
  57. 57.
    Sibrack, C D, Gutman, L T, Wilfert, C M, Maren, C, Glair, M G St, Keller, P M.: Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J. infect. Dis. 146, 673–682 (1982).CrossRefPubMedGoogle Scholar
  58. 58.
    Silvestri, D L, Corey, L, Holmes, K K: Ineffectivness of topical idoxuridine in dimethylsulfoxide for therapy for genital herpes. JAMA 248, 953–959 (1982).CrossRefPubMedGoogle Scholar
  59. 59.
    Steele, R W, Keeney, R E, Bradsher, R W, Moses, E B, Soloff, B L.: Treatment of varicellazoster meningoencephalitis with acyclovir-demonstration of virus in cerebrospinal fluid by electron microscopy. Amer. J. clin. Path. 80, 57–60 (1983).Google Scholar
  60. 60.
    Stiehm, E R, Kronenberg, L H, Rosenblatt, H M, Bryson, Y, Merigan, TC.: Interferon: Immunobiology and clinical significance. Ann. intern. Med. 96, 80–93 (1982).PubMedGoogle Scholar
  61. 61.
    Straus, S, Seidlin, M, Takiff, H, Bachrach, S, Di Giovanna, J, Western, K: Suppression of recurrent genital herpes with oral acyclovir. Clin. Res. 31, 543A (1983).Google Scholar
  62. 62.
    Swart, R N J, Vermeer, B J, Meer, J W M van der, Enschede, F A J, Versteeg, J.: Treatment of eczema herpeticum with acyclovir. Arch. Derm. 119, 13–16 (1983).CrossRefPubMedGoogle Scholar
  63. 63.
    Teh, C Z, Sacks, S L.: Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2/-deoxyuridine: Preferential inhibition of herpes simplex virus type 2. Antimicrob. Agents Chemother. 23, 637–640 (1983).PubMedGoogle Scholar
  64. 64.
    Theml, H, Siegert, W, Ziegler, H W L, Huhn, D.: Interferon, eine der interessantesten biologischen Substanzen, aber kein Allheilmittel. Med. Klin. 77, 132–139 (1982).Google Scholar
  65. 65.
    Thin, R N, Nabarro, J M, Parker, J D, Fiddian, A P.: Topical acyclovir in the treatment of initial genital herpes. Brit. J. vener. Dis. 59, 116–119 (1983).Google Scholar
  66. 66.
    Walle, van der H B, Malten, K E, Wargemakers, T H.: Contactallergie voor tromantadine (Viru Merz) bij de Behandeling van Herpes simplex infecties. Ned. T. Geneesk. 126, 1033–1035 (1982).PubMedGoogle Scholar
  67. 67.
    Wallin, J, Lernestedt, L O, Lycke, E.: Treatment of recurrent herpes labialis with trisodium phosphonoformiate. Antivirals 8, 1361–1363 (1979).Google Scholar
  68. 68.
    Wassilew, S W.: Acyclovir (Zovirax®). Arzneimittelther 1. Jahrg, 4 (1983).Google Scholar
  69. 69.
    Wassilew, S W.: Möglichkeiten und Grenzen der Chemotherapie bei Erkrankungen durch das Herpes simplex- und das Varicella-Zoster-Virus. Hautarzt 24, 1–5 (1983).Google Scholar
  70. 70.
    Whitley, R J, Soong, S J, Hirsch, M S, Karchmer, A W, Dolin, R, Calasso, G, Dunnick, J K, Alford, CA.: Herpes simplex encephalitis. Vidarabine therapy and diagnostic problems. New Engl. J. Med. 304, 313–318 (1981).Google Scholar
  71. 71.
    Whitley, R J, Ch’ien, L T, Dolin, R, Galasso, G, Alford, CA, and editors of the Collaborative Study Group.: Adenine arabinoside therapy of herpes zoster in the immunosuppressed: NIAID collaborative antiviral study. New Engl. J. Med. 294, 1193–1199 (1976).Google Scholar
  72. 72.
    Whitley, R J, and the NIAID Collaborative Antiviral Study Group: Interim summary of mortality in herpes simplex encephalitis and neonatal herpes simplex virus infections: vidarabine versus acyclovir. J. antimicrob. Chemother. 12, Suppl. B, 105–112 (1983).Google Scholar
  73. 73.
    Wildenhoff, K E, Esmann, V, Ipsen, J, Harving, H, Peterslund, N A, Schonhey der, H.: Treatment of trigeminal and thoracic zoster with idoxuridine. Scand. J. infect. Dis. 13, 251–262.(1981).Google Scholar
  74. 74.
    Yeo, J M, Fiddian, A P.: Acyclovir in the management of herpes.labialis. J. antimicrob. Chemother. 12, Suppl. B, 95–103 (1983).PubMedGoogle Scholar
  75. 75.
    Yokota, T, Shigeta, S, Iwabuchi, T, Ogata, M, Takami, Z.: Mutant strain of varicella zoster virus deficient in thymidine kinase- inducing activity. In: Herpesvirus. Clinical pharmacological and basic aspects. Proc. Excerpta Medica Int. Congr. Ser. pp 102–105 (1982).Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • S. W. Wassilew
    • 1
  • Th. Nasemann
    • 1
  1. 1.Universitäts-Hautklinik HamburgHamburg 20Deutschland

Personalised recommendations